{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:57Z","timestamp":1762505457658},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1097\/coc.0b013e318162f57d","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T21:40:54Z","timestamp":1236289254000},"page":"317-322","source":"Crossref","is-referenced-by-count":31,"title":["Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"Y","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucille A.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen I.","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiguo G.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Longmate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra P.","family":"Belani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005.","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(04)01508-6","article-title":"Systemic treatment and liver transplantation or hepatocellular carcinoma: two sides of the therapeutic spectrum.","volume":"5","author":"Burroughs","year":"","journal-title":"Lancet Oncol"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-108-3-390","article-title":"Hepatocellular carcinoma.","volume":"108","author":"Di Bisceglie","year":"1998","journal-title":"Ann Intern Med"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.1994.12.6.1323","article-title":"Treatment of hepatocellular carcinoma: too many options?","volume":"12","author":"Venook","year":"1994","journal-title":"J Clin Oncol"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0305-7372(88)90007-2","article-title":"Clinical trials in primary hepatocellular carcinoma: current status and future directions.","volume":"15","author":"Nerenstone","year":"1988","journal-title":"Cancer Treat Rev"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/1097-0142(19830115)51:2<206::AID-CNCR2820510206>3.0.CO;2-P","article-title":"Induction of remission in hepatocellular carcinoma: a comparison of VP-16 and adriamycin.","volume":"51","author":"Melia","year":"1983","journal-title":"Cancer"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/BF00258459","article-title":"Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.","volume":"23","author":"Lai","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000227142","article-title":"A phase 2 study of cisplatin in patients with hepatocellular carcinoma.","volume":"50","author":"Okada","year":"1993","journal-title":"Oncology"},{"key":"R9-2-20210128","first-page":"63","article-title":"Chemotherapy of Hepatic Tumors.","author":"Lewis","year":"1984"},{"key":"R10-2-20210128","first-page":"750","article-title":"Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.","author":"Yang","year":"2000","journal-title":"Am Cancer Soc"},{"key":"R11-2-20210128","first-page":"9","article-title":"Accumulation of cis-diammine-dichloroplatinum (II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.","volume":"48","author":"Kraker","year":"1988","journal-title":"Cancer Res"},{"key":"R12-2-20210128","first-page":"5970","article-title":"In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.","volume":"53","author":"Pendyala","year":"1993","journal-title":"Cancer Res"},{"key":"R13-2-20210128","first-page":"1376","article-title":"Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum; L-OHP) with CDDP on various cells: correlation with intracellular accumulation.","volume":"10","author":"Silvestro","year":"1990","journal-title":"Anticancer Res"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","article-title":"Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.","volume":"52","author":"Rixe","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"R15-2-20210128","first-page":"393","article-title":"Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.","volume":"15","author":"Fukuda","year":"1995","journal-title":"Anticancer Res"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/S0002-9440(10)64329-5","article-title":"Down-regulation of growth arrest DNA damage-inducible gene 45\u03b2 expression is associated with human hepatocellular carcinoma.","volume":"162","author":"Qui","year":"2003","journal-title":"Am J Pathol"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63425-6","article-title":"Hypermethylation of growth arrest DNA damage-inducible gene 45b promoter in human hepatocellular carcinoma.","volume":"165","author":"Qiu","year":"2004","journal-title":"Am J Pathol"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.bjc.6601369","article-title":"Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.","volume":"89","author":"Guan","year":"2003","journal-title":"Br J Cancer"},{"key":"R19-2-20210128","first-page":"A880","article-title":"Comparison of cytotoxicity of oxaliplatin, cisplatin and carboplatin in human neuroblastoma (NB) cell lines.","volume":"16","author":"Riccardi","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005800520747","article-title":"Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.","volume":"15","author":"Dunn","year":"1997","journal-title":"Invest New Drugs"},{"key":"R21-2-20210128","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity.","volume":"25","author":"Raymond","year":"1998","journal-title":"Sem Oncol"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1021\/jm00137a007","article-title":"Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl) cyclohexyla-mine isomers against leukemia P388.","volume":"24","author":"Noji","year":"1981","journal-title":"J Med Chem"},{"key":"R23-2-20210128","first-page":"A20","article-title":"Mechanism of the in vitro synergism between SN38 and oxaliplatin.","volume":"38","author":"Zeghari-Squalli","year":"1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R24-2-20210128","first-page":"A927","article-title":"CPT-11\/Oxaliplatin (L-OHP) every two weeks: A Phase II study in patients (PTS) with advanced digestive tumors.","volume":"17","author":"Goldwasser","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00001813-199710000-00009","article-title":"Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.","volume":"8","author":"Raymond","year":"1997","journal-title":"Anticancer Drugs"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000421-200808000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:50:29Z","timestamp":1618033829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-200808000-00002"}},"subtitle":["A California Cancer Consortium Trial"],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e318162f57d","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}